Related Experiment Video
Updated: Aug 13, 2025
Chitosan/Interfering RNA Nanoparticle Mediated Gene Silencing in Disease Vector Mosquito Larvae
Published on: March 25, 2015
Chitosan loaded RNA polymerase inhibitor nanoparticles increased attenuation in toxin release from Streptococcus
Fulwah Yahya Alqahtani1, Fadilah Sfouq Aleanizy1, Hamad M Alkahtani2
1Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh 11495, Saudi Arabia.
Background:
Multidrug-resistant (MDR) bacterial infections have become an emerging health concern around the world. Antibiotics resistance among S. pneumoniae strains increased recently contributing to increase in incidence of pneumococcal infection. This necessitates the discovery of novel antipnemococcal such as compound C3-005 which target the interaction between RNA polymerase and σ factors. Chitosan nanoparticles (CNPs) exhibited antibacterial activity including S. pneumonia. Therefore, the aims of the current investigation were to formulate CNPs loaded with C3-005 and characteristic their antimicrobial properties against S. pneumonia.
Methods:
The CNPs and C3-005 loaded CNPs were produced utilizing ionic gelation method, and their physicochemical characteristics including particle size, zeta potential, polydispersity index (PDI), encapsulation efficiency (EE%), and in vitro release profile were studied. Both differential scanning calorimetry (DSC) and fourier transform infrared spectroscopy (FTIR) were used for chemical characterization. The synthesized NPs' minimum inhibitory concentration (MIC) was determined using killing assay and broth dilution method, and their impact on bacteria induced hemolysis were also studied.
Results:
The NPs encapsulating C3-005 were successfully prepared with particle size of 343.5 nm ± 1.3, zeta potential of 29.8 ± 0.37, and PDI of 0.20 ± 0.03. 70 % of C3-005 were encapsulated in CNPs and sustained release pattern of C3-005 from CNPs was revealed by an in vitro release study. CNPs containing C3-005 exhibited higher antipnomcoccal activity with MIC50 of 30 µg/ml when compared with C3-005 and empty CNPs alone. The prepared C3-CNPs showed a reduction of bacterial hemolysis in a concentration-related (dependent) manner and was higher than C3-005 alone.
Conclusions:
The findings of this study showed the potential for using C3-005 loaded CNPs to treat pneumococcal infection.
Insights
Novel chitosan nanoparticles (CNPs) loaded with compound C3-005 show significant antimicrobial activity against Streptococcus pneumoniae. This formulation offers a promising strategy to combat multidrug-resistant pneumococcal infections.
Area of Science:
- Nanotechnology
- Microbiology
- Pharmacology
Background:
- Multidrug-resistant bacterial infections, particularly from Streptococcus pneumoniae, pose a growing global health threat.
- Increasing antibiotic resistance necessitates the development of novel antimicrobial agents targeting essential bacterial processes.
- Compound C3-005 targets the interaction between RNA polymerase and sigma factors, offering a new therapeutic avenue.
Purpose of the Study:
- To formulate chitosan nanoparticles (CNPs) loaded with the novel antipneumococcal compound C3-005.
- To characterize the physicochemical properties of the C3-005 loaded CNPs.
- To evaluate the antimicrobial efficacy of C3-005 loaded CNPs against Streptococcus pneumoniae.
Main Methods:
- Chitosan nanoparticles (CNPs) loaded with C3-005 were prepared using the ionic gelation method.
- Physicochemical characterization included particle size, zeta potential, polydispersity index (PDI), and encapsulation efficiency (EE%).
- Antimicrobial activity was assessed via minimum inhibitory concentration (MIC) determination and bacterial hemolysis assays.
Main Results:
- Successfully formulated C3-005 loaded CNPs with a particle size of 343.5 nm, zeta potential of 29.8, and PDI of 0.20.
- Achieved 70% encapsulation efficiency for C3-005 with sustained in vitro release.
- C3-005 loaded CNPs demonstrated enhanced antipneumococcal activity (MIC50 of 30 µg/ml) and superior reduction of bacterial hemolysis compared to C3-005 alone.
Conclusions:
- C3-005 loaded CNPs exhibit significant potential as an effective therapeutic agent against Streptococcus pneumoniae infections.
- The developed formulation offers a promising approach to address the challenge of multidrug-resistant pneumococcal infections.
More Related Videos
Related Concept Videos
01:23RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
01:23Types of RNA
Three main types of RNA are involved in protein synthesis: messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). These RNAs perform diverse functions and can be broadly classified as protein-coding or non-coding RNA. Non-coding RNAs play important roles in the regulation of gene expression in response to developmental and environmental changes. Non-coding RNAs in prokaryotes can be manipulated to develop more effective antibacterial drugs for human or animal use.
RNA...
02:15Experimental RNAi